- 2025-04-22WithdrawnApplication Rop 265
Milan Central Division allowed Pfizer's withdrawal of the revocation action and the counterclaim for revocation concerning GlaxoSmithKline's EP 4 183 412 (RSV vaccine patent), allowing GSK to withdraw its corresponding patent amendment application. Proceedings were declared closed. Each party bears its own costs. The request for 60% court fee reimbursement was allowed.